Artist's rendition of a yellow CAR T cell near a red cancer cell surrounded by red blood cells.
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free
First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free

First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.

First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.

CAR T cells
knitted pink heart with a mended hole
CAR T Cells Mend Broken Mouse Hearts
Sophie Fessl | Jan 6, 2022
Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Amanda Heidt | Mar 26, 2021
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
A full blood sample vial lying on top of a piece of paper that reads “Acute lymphoblastic leukemia”.
Targeting Leukemia with T Cells That Avoid Self-Destruction
Deanna MacNeil, PhD
Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers.
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena | Mar 5, 2021
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
CAR T cells, oncolytic virus, CD19, mouse model, solid cancer, liquid cancer, tumor, immune response, immunotherapy, T cell, treatment
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
A wrecking ball destroying a malignant cell as a 3D illustration
Armored CAR T Cells Break Through Immune Suppression in Solid Tumors
Jennifer Zieba, PhD
Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020
There’s a new cell-based cancer immunotherapy on the block.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
Overcoming T Cell Therapy Barriers with Engineered Proteins
Overcoming T Cell Therapy Barriers with Engineered Proteins
The Scientist Creative Services Team
Shannon Oda will discuss how to develop novel engineered fusion proteins to improve T cell therapies against hematological and solid tumors.
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
Ashley Yeager | Feb 6, 2020
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
car t chimeric antigen receptor t cell immunotherapy pyroptosis cell death perforin macrophage leukemia lymphoma
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
An Improved Way to Detect CAR T Cells and SARS-CoV-2-Binding Cells
Technique Talk: An Improved Way to Detect CAR T Cells and SARS-CoV-2-Binding Cells
The Scientist Creative Services Team and Bio-Techne
Jody Bonnevier will discuss the advantages of Fluorokines™ for detecting and investigating CAR T cells and other key drivers of the immune system.
A Bright Scientific Future
Bob Grant | Jan 13, 2020
We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.
cardiac fibrosis car t chimeric antigen receptor immunotherapy t cells fibroblasts cardiovascular disease
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Emma Yasinski | Sep 11, 2019
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
800x560 istock image
Training Immune Cells to Be Cancer Killers
Aparna Nathan
A career-altering experience as a cancer patient motivated one researcher to design more potent immunotherapies.
cryopreservation facility
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
car t cell chimeric antigen receptor b cell lymphoma cd19 kymriah yescarta
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
Finding CAR T Cells in Solid Tumors by Single-Cell Resolution
Finding CAR T Cells in Solid Tumors at Single-Cell Resolution
The Scientist Creative Services Team in collaboration with Miltenyi Biotec
Rita Pfeifer will discuss visualizing and quantifying CAR T-cell infiltration into solid tumors with 3-D light sheet fluorescence microscopy (LSFM).
Chronic lymphocytic leukemia
T Cell Proliferation Linked to CAR T Responses
Ashley Yeager | Jul 15, 2019
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.